Welcome to our dedicated page for RXO SEC filings (Ticker: RXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RXO, Inc. filings document the formal disclosures of an NYSE-listed asset-light transportation company with common stock traded under RXO. Recent Form 8-K reports furnish quarterly operating results, related investor presentations, Regulation FD materials, senior unsecured notes disclosures, and asset-based revolving credit facility agreements tied to the company's transportation brokerage and logistics operations.
Proxy materials disclose board elections, auditor ratification, executive compensation votes and amendments to the RXO, Inc. 2022 Omnibus Incentive Compensation Plan. Other material-event filings cover officer appointments, subsidiary guarantees, debt redemption terms, collateral and borrowing-base mechanics, and capital-structure disclosures involving senior notes and revolving credit arrangements.
RXO, Inc. reported an insider equity transaction by one of its directors on 01/02/2026. The director acquired 7,745 shares of common stock at a price of $0 through the conversion of previously granted restricted stock units (transaction code M), bringing direct ownership to 34,275 common shares.
On the same date, the director received a new award of 14,517 restricted stock units (RSUs), each representing the right to receive either one share of common stock or a cash payment equal to its fair market value upon settlement. These RSUs are scheduled to vest in full on January 2, 2027, provided the director continues to serve on the board. Previously granted RSUs vested on January 2, 2026, triggering the share acquisition.
RXO, Inc. (RXO) director reported an open-market purchase of company stock. On 11/20/2025, the reporting person bought 8,317 shares of RXO common stock in a transaction coded "P" (purchase), at a weighted average price of $10.61 per share, within a price range of $10.45 to $10.75.
Following this transaction, the director beneficially owns 275,416 shares of RXO common stock directly. The filing notes that detailed trade data by price level is available upon request.
RXO, Inc. director reported an open-market purchase of 9,350 shares of common stock on 11/17/2025 at a weighted average price of $10.75, bringing direct ownership to 91,137 shares.
The filing also shows beneficial ownership of restricted stock units (RSUs), including 7,745 RSUs that vest in full on January 2, 2026, and 126,260 RSUs that have vested and are subject to a deferral election. Each RSU represents the right to receive either one share of RXO common stock or a cash amount equal to its fair market value upon settlement.
The amendment was made solely to voluntarily include the director’s beneficial ownership of RSUs reported in Table II.
RXO, Inc. reported an insider share purchase by a company director. On 11/17/2025, the reporting person bought 9,350 shares of RXO common stock in the open market, coded as a purchase transaction.
The weighted average purchase price was $10.75 per share, with individual trades ranging from $10.74 to $10.76. Following this transaction, the director directly beneficially owns 91,137 shares of RXO common stock.
RXO, Inc. (RXO) reported an insider equity transaction by its Chief Executive Officer and Director. On 11/14/2025, 1,565 Restricted Stock Units (RSUs) were converted into an equal number of shares of common stock at an exercise price of $0, reflecting scheduled vesting of a prior equity award. To cover related tax obligations, 684 shares of common stock were withheld by the company at a price of $10.86 per share, with no open market sales by the reporting person.
After these transactions, the reporting person directly owned 4,731 shares of RXO common stock and also had indirect holdings of 7,775 shares held by a trust and 271,767 shares held through a controlled limited liability company. The reporting person also beneficially owned 605,967 derivative securities in the form of RSUs, including 74,932 RSUs previously reported, which each represent the right to receive one share of common stock or an equivalent cash amount upon settlement under the award’s vesting schedule.
RXO, Inc. — Schedule 13G/A ownership update. Orbis Investment Management Limited and related advisers reported beneficial ownership of RXO common stock, reflecting a significant passive stake as of the event date 09/30/2025.
The filing lists an aggregate 32,573,158 shares beneficially owned, representing 19.9% of the class. Within this total, Orbis Investment Management Limited has sole voting and dispositive power over 31,581,774 shares; Orbis Investment Management (U.S.), L.P. has 963,408 shares; and Allan Gray Australia Pty Ltd has 27,976 shares. The reporting persons certify the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
RXO, Inc. reported an insider transaction on a Form 4: the Chief Accounting Officer sold 33,343 shares of common stock on 11/10/2025 (transaction code S) at a weighted average price of $11.57, with individual sale prices ranging from $11.51 to $11.68. Following the sale, the reporting person directly owned 43,558 shares.
RXO, Inc. — Form 4 insider transaction
A company director reported transactions on November 7, 2025. The filing shows a purchase of 20,308 shares of common stock at $12.37 per share, held indirectly by a trust. The director also reported transfers coded “G” for no consideration, moving 36,508 shares from the trust and 13,034 shares from direct ownership.
Per the explanation, the director transferred an aggregate of 49,542 shares to a grantor retained annuity trust (GRAT), where the director is trustee and sole beneficiary. Following these transactions, 49,542 shares were listed as indirectly owned by the GRAT.
RXO, Inc. reported an insider purchase by its Chief Executive Officer and director on 11/10/2025. The filing lists two open‑market buys: 7,775 shares and 3,850 shares. The purchase price ranged from $12.80–$12.89, with a weighted average purchase price of $12.88.
Following these transactions, beneficial ownership is shown in three lines: 7,775 shares held indirectly by a trust, 3,850 shares held directly, and 271,767 shares held indirectly through a limited liability company controlled by the reporting person.
RXO has a Form 144 notice for a proposed sale of 33,343 shares of common stock. The filing lists Morgan Stanley Smith Barney LLC as broker, with an approximate sale date of 11/10/2025 on the NYSE. The reported aggregate market value is $494,748.54.
The shares come from equity awards: performance shares acquired on 11/01/2022 (26,073 shares) and restricted stock acquired on 02/23/2024, 02/23/2025, and 03/22/2025 (totaling 7,270 shares). Shares outstanding were 164,111,872; this is a baseline figure, not the amount being sold.